Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1988 1
1989 1
1999 1
2002 1
2003 1
2004 2
2006 1
2007 2
2008 1
2009 2
2010 3
2011 3
2012 7
2013 8
2014 1
2015 1
2016 4
2017 5
2018 8
2019 5
2020 8
2021 5
2022 3
2023 2
2024 4
2025 2
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Parkinson's disease.
Bloem BR, Okun MS, Klein C. Bloem BR, et al. Lancet. 2021 Jun 12;397(10291):2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10. Lancet. 2021. PMID: 33848468 Review.
Diagnosis and Treatment of Parkinson Disease: A Review.
Armstrong MJ, Okun MS. Armstrong MJ, et al. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. JAMA. 2020. PMID: 32044947 Review.
IMPORTANCE: Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease-like movement problems such as rigidity, slowness, and tremor. ...Nonmotor symptoms require nondopaminergic approaches (eg, selective serotonin r …
IMPORTANCE: Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease-like …
Parkinson's disease as a somato-cognitive action network disorder.
Ren J, Zhang W, Dahmani L, Gordon EM, Li S, Zhou Y, Long Y, Huang J, Zhu Y, Guo N, Jiang C, Zhang F, Bai Y, Wei W, Wu Y, Bush A, Vissani M, Wei L, Oehrn CR, Morrison MA, Zhu Y, Zhang C, Hu Q, Yin Y, Cui W, Fu X, Zhang P, Wang W, Ji GJ, He J, Wang K, Fan D, Wang Z, Kimberley T, Little S, Starr PA, Richardson RM, Li L, Wang M, Wang D, Dosenbach NUF, Liu H. Ren J, et al. Nature. 2026 Mar;651(8107):1030-1038. doi: 10.1038/s41586-025-10059-1. Epub 2026 Feb 4. Nature. 2026. PMID: 41639440 Free PMC article.
Parkinson's disease (PD) is an incurable neurological disorder that often begins insidiously with sleep disturbances and somatic symptoms, progressing to whole-body motor and cognitive symptoms(1-5). ...To investigate the role of the SCAN in PD pathophysiology and treatmen …
Parkinson's disease (PD) is an incurable neurological disorder that often begins insidiously with sleep disturbances and somatic symp …
Trial of Deferiprone in Parkinson's Disease.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Devos D, et al. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254. N Engl J Med. 2022. PMID: 36449420 Clinical Trial.
Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. ...
Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content …
Phenylalanine Effects on Brain Function in Adult Phenylketonuria.
Pilotto A, Zipser CM, Leks E, Haas D, Gramer G, Freisinger P, Schaeffer E, Liepelt-Scarfone I, Brockmann K, Maetzler W, Schulte C, Deuschle C, Hauser AK, Hoffmann GF, Scheffler K, van Spronsen FJ, Padovani A, Trefz F, Berg D. Pilotto A, et al. Neurology. 2021 Jan 19;96(3):e399-e411. doi: 10.1212/WNL.0000000000011088. Epub 2020 Oct 22. Neurology. 2021. PMID: 33093221
OBJECTIVE: To evaluate the relationship between circulating phenylalanine and brain function as well as neuropsychiatric symptoms in adults with phenylketonuria. ...RESULTS: Nineteen patients with phenylketonuria (median age 41 years) with different phenylalanine …
OBJECTIVE: To evaluate the relationship between circulating phenylalanine and brain function as well as neuropsychiatric sympt …
The role of L-DOPA in neurological and neurodegenerative complications: a review.
Kulkarni SR, Thokchom B, Abbigeri MB, Bhavi SM, Singh SR, Metri N, Yarajarla RB. Kulkarni SR, et al. Mol Cell Biochem. 2025 Oct;480(10):5221-5242. doi: 10.1007/s11010-025-05324-w. Epub 2025 Jun 9. Mol Cell Biochem. 2025. PMID: 40488810 Review.
Its ability to cross the blood-brain barrier (BBB) makes it a crucial therapeutic agent for restoring dopaminergic neurotransmission, thereby influencing motor function, cognition, and neuroprotection. ...Furthermore, L-DOPA has demonstrated efficacy in neurologi …
Its ability to cross the blood-brain barrier (BBB) makes it a crucial therapeutic agent for restoring dopaminergic neurotransmission, …
Bidirectional regulation of levodopa-induced dyskinesia by a specific neural ensemble in globus pallidus external segment.
Shen C, Shen B, Liu D, Han L, Zou K, Gan L, Ren J, Wu B, Tang Y, Zhao J, Sun Y, Liu F, Yu W, Yao H, Wu J, Wang J. Shen C, et al. Cell Rep Med. 2024 Jun 18;5(6):101566. doi: 10.1016/j.xcrm.2024.101566. Epub 2024 May 16. Cell Rep Med. 2024. PMID: 38759649 Free PMC article.
Here, we utilize the activity-dependent tool to identify three brain regions (globus pallidus external segment [GPe], parafascicular thalamic nucleus, and subthalamic nucleus) that specifically contain dyskinesia-activated ensembles. ...
Here, we utilize the activity-dependent tool to identify three brain regions (globus pallidus external segment [GPe], parafascicular …
Freezing of Gait Before Levodopa.
Nonnekes J, Koehler P, Bloem BR. Nonnekes J, et al. J Parkinsons Dis. 2021;11(4):2093-2094. doi: 10.3233/JPD-212933. J Parkinsons Dis. 2021. PMID: 34511514 Free PMC article. No abstract available.
l-Dopa in dystonia: A modern perspective.
Maas RPPWM, Wassenberg T, Lin JP, van de Warrenburg BPC, Willemsen MAAP. Maas RPPWM, et al. Neurology. 2017 May 9;88(19):1865-1871. doi: 10.1212/WNL.0000000000003897. Epub 2017 Apr 7. Neurology. 2017. PMID: 28389587 Review.
We here provide a historical perspective on this statement, discuss the current diagnostic and therapeutic applications of l-dopa in everyday neurologic practice, contrast these with its approved indications, and finish with our view on both a diagnostic and therapeutic tr …
We here provide a historical perspective on this statement, discuss the current diagnostic and therapeutic applications of l-dopa in everyda …
Metabolic control and clinical outcome in adolescents with phenylketonuria.
De Giorgi A, Nardecchia F, Romani C, Leuzzi V. De Giorgi A, et al. Mol Genet Metab. 2023 Nov;140(3):107684. doi: 10.1016/j.ymgme.2023.107684. Epub 2023 Aug 12. Mol Genet Metab. 2023. PMID: 37672857
The main neurological, cognitive, and behavioural consequences of phenylketonuria have been eradicated thanks to new-born screening and Phe-restricted diet therapy. However, the effects of high phenylalanine levels during adolescence and adulthood on neurocognitive …
The main neurological, cognitive, and behavioural consequences of phenylketonuria have been eradicated thanks to new-born screening a …
73 results